Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28241825
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
BMC Med
2017[Feb]; 15
(1
): 45
PMID28241825
show ga
Non-alcoholic fatty liver disease has emerged a major challenge because of it
prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved
therapies. As the burden of hepatitis C abates over the next decade,
non-alcoholic fatty liver disease will become the major form of chronic liver
disease in adults and children and could become the leading indication for liver
transplantation. This overview briefly summarizes the most recent data on the
pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease.
Ongoing clinical trials are focused on an array of disease mechanisms and
reviewed here are how these treatments fit into the current paradigm of substrate
overload lipotoxic liver injury. Many of the approaches are directed at
downstream events such as inflammation, injury and fibrogenesis. Addressing more
proximal processes such as dysfunctional satiety mechanisms and inappropriately
parsimonious energy dissipation are potential therapeutic opportunities that if
successfully understood and exploited would not only address fatty liver disease
but also the other components of the metabolic syndrome such as obesity, diabetes
and dyslipidemia.
free
free
free
